Engineered T-Cells take on HIV in early trial
NCT ID NCT03617198
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tests a new approach to HIV treatment. Researchers take a person's own T-cells, modify them to better recognize and attack HIV, and infuse them back. The main goal is to check safety in 12 stable HIV patients, while also seeing if the modified cells can help control the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified T-cells (CD4 CAR+CCR5 ZFN T-cells)
What this could lead to
If successful, this could point toward a way to control HIV without daily medication, by training the immune system to attack infected cells.
What could go wrong
This is a very early, small safety trial with only 12 people. The modified cells may not work as hoped, and there are risks of side effects from the cell infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States